Minor
AMPLIFY · Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Primary and study completion pushed from Jan 31, 2027 to Apr 30, 2027
Acerta Pharma BVPhase 3 NCT03836261 Registry history of NCT03836261 on ClinicalTrials.gov (opens the registry)